Baena, AMG, Mir, MC, Faja, GV, Osorio, LJM, Vilaseca, VG. Inflammatory myopathies with anti-TIF1y antibodies and their association with neoplasms: a study of a series of 28 cases. MEDICINA CLINICA. 2026; 166(8)DOI:10.1016/j.medcli.2026.107496. PMID:. IF:2.100(Q2/3D).

Slusarczyk, A, Moschini, M, Krajewski, W, Scilipoti, P, Velasco, JC, Mertens, LS, Mori, K, Subiela, JD, Garbas, K, Duran, PD, Claps, F, Contieri, R, Domanski, P, Tully, K, Grobet-Jeandin, E, Puentedura, AL, Lijnen, RAG, Fertitta, G, Longoni, M, Del Giudice, F, Gallioli, A, Laukhtina, E, Marcq, G, Mari, A, Amodeo, A, Afferi, L, Albisinni, S, Boorjian, SA, Soria, F, Briganti, A, Shariat, SF, Gontero, P, Radziszewski, P, Pradere, B. Bladder Tumor Location Matters: Trigone and Bladder Neck Involvement Predict Worse Oncological Outcomes in High-Grade Non-Muscle-Invasive Bladder Cancer. ANNALS OF SURGICAL ONCOLOGY. 2026; 33(8)DOI:10.1245/s10434-026-19476-6. PMID:41862762. IF:3.500(Q1/2D).

Gonzalez, JA, Sebio, A, Martin-Broto, J, Hindi, N, Villarejo-Campos, P, Jiménez, M, Díaz-Beveridge, R, Castellanos, JFO, Andújar, RL, Alvarez, RA, Asencio, JM, Serrano, C, Conde, NR, Boix, SC, Krauel, L, Codina, HC, García, JAT, de Llanos, EL, Ninou, AH, Campos, AP, Gruber, AK, Pousa, AL. ASO Visual Abstract: First-in-Human Study of CEB-01: Novel Loco-Regional SN-38-Releasing Membrane to Prevent Local Recurrence in Retroperitoneal Sarcomas. ANNALS OF SURGICAL ONCOLOGY. 2026; 33(8)DOI:10.1245/s10434-026-19614-0. PMID:41984420. IF:3.500(Q1/2D).

Gonzalez, JA, Sebio, A, Martin-Broto, J, Hindi, N, Villarejo-Campos, P, Jiménez, M, Díaz-Beveridge, R, Castellanos, JFO, Andújar, RL, Alvarez, RA, Asencio, JM, Serrano, C, Conde, NR, Boix, SC, Krauel, L, Codina, HC, García, JAT, de Llanos, EL, Ninou, AH, Campos, AP, Gruber, AK, Pousa, AL. First-in-Human Study of CEB-01: Novel Loco-Regional SN-38-Releasing Membrane to Prevent Local Recurrence in Retroperitoneal Sarcomas. ANNALS OF SURGICAL ONCOLOGY. 2026; 33(8)DOI:10.1245/s10434-026-19487-3. PMID:41998462. IF:3.500(Q1/2D).

Di Grazia, G, Di Lauro, V, Morchón-Araujo, D, Nucera, S, Figuero-Pérez, L, Calleja-Holgado, FJ, Sánchez, DP, Wallbaum, B, Vargas, PR, Palleschi, M, Musolino, A, Cobos, GZ, Paradis, AL, Barroso, G, Cano, OC, Portulas, ED, Caltavituro, A, Buono, G, Gillaranz, YJ, Echavarria, I, López-Tarruella, S, Sirvén, MB, Martinez-Sáez, O, Adamo, B, Mun, M, Arpino, G, Bayona, RS, De Laurentiis, M, Rodriguez, CA, Pascual, T, Losada, MV, Schettini, F. Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching (vol 242 , 116818 , 2026 ). EUROPEAN JOURNAL OF CANCER. 2026; 243DOI:10.1016/j.ejca.2026.116852. PMID:42250453. IF:7.100(Q1/2D).

Ahrens, M, Haanen, J, Albiges, L, Goupil, MG, Boleti, E, Gravis, G, Fléchon, A, Grimm, MO, Bedke, J, Barthélémy, P, Castellano, D, Mellado, B, Ivanyi, P, Rottey, S, Flörcken, A, Suárez, C, Maroto, JP, Grünwald, V, Oosting, S, Kopecky, J, Zschäbitz, S, Boegemann, M, Buchler, T, Niegisch, G, Goebell, PJ, Waddell, T, Joly, F, Priou, F, Retz, M, Siemer, S, Zimmermann, U, Deckbar, D, Burkholder, I, Hartmann, A, Bergmann, L. Papillary renal cell carcinoma-exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review. EUROPEAN JOURNAL OF CANCER. 2026; 243DOI:10.1016/j.ejca.2026.116816. PMID:42235464. IF:7.100(Q1/2D).